|
Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung …
Wall Street Journal Secondary efficacy endpoints in the proof-of-concept study were also achieved, including reduced short-acting beta agonist use; asthma control; forced vital capacity improvement; symptom-free days during treatment; and improvement in rhinasthma and … Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In … Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial |
View full post on asthma – Google News